From the late 1980s, a storm surrounding the wisdom, ethics, and economics of human gene patents has been brewing. The various winds of concern in this storm touched on the impact of gene patents on ...

-- Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 loss‐of‐function cancers; expect to initiate Phase 1b/2a clinical trial in solid tumors in mid-2026 -- SOUTH SAN FRANCISCO, ...